- Home
- DCGO vs HURA Comparison
DCGO vs HURA Comparison
Compare DCGO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- HURA
- Stock Information
- Founded
- DCGO 2015
- HURA 2009
- Country
- DCGO United States
- HURA United States
- Employees
- DCGO N/A
- HURA N/A
- Industry
- DCGO Managed Health Care
- HURA
- Sector
- DCGO Health Care
- HURA
- Exchange
- DCGO Nasdaq
- HURA Nasdaq
- Market Cap
- DCGO 139.7M
- HURA 145.6M
- IPO Year
- DCGO N/A
- HURA N/A
- Fundamental
- Price
- DCGO $1.58
- HURA $2.63
- Analyst Decision
- DCGO Strong Buy
- HURA Strong Buy
- Analyst Count
- DCGO 4
- HURA 2
- Target Price
- DCGO $3.78
- HURA $11.50
- AVG Volume (30 Days)
- DCGO 454.9K
- HURA 819.1K
- Earning Date
- DCGO 11-06-2025
- HURA 08-14-2025
- Dividend Yield
- DCGO N/A
- HURA N/A
- EPS Growth
- DCGO N/A
- HURA N/A
- EPS
- DCGO N/A
- HURA N/A
- Revenue
- DCGO $435,968,564.00
- HURA N/A
- Revenue This Year
- DCGO N/A
- HURA N/A
- Revenue Next Year
- DCGO N/A
- HURA N/A
- P/E Ratio
- DCGO N/A
- HURA N/A
- Revenue Growth
- DCGO N/A
- HURA N/A
- 52 Week Low
- DCGO $1.23
- HURA $1.80
- 52 Week High
- DCGO $5.68
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- DCGO 50.17
- HURA 46.46
- Support Level
- DCGO $1.48
- HURA $2.43
- Resistance Level
- DCGO $1.60
- HURA $3.30
- Average True Range (ATR)
- DCGO 0.07
- HURA 0.18
- MACD
- DCGO -0.01
- HURA -0.05
- Stochastic Oscillator
- DCGO 37.25
- HURA 24.14
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.